The Europe Huntington's Disease Treatment Market would witness market growth of 8.8% CAGR during the forecast period (2024-2031).
The Germany market dominated the Europe Huntington's Disease Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $51,954.4 Thousands by 2031. The UK market is exhibiting a CAGR of 7.9% during (2024 - 2031). Additionally, The France market would experience a CAGR of 9.7% during (2024 - 2031).
Disease-modifying therapies aim to alter the course of Huntington’s Disease by targeting the underlying genetic and biological mechanisms driving neurodegeneration. The goal of antisense oligonucleotide (ASO) and RNA interference (RNAi) therapy is to decrease the generation of mutant huntingtin protein (mHTT), which is neurotoxic. These therapies slow disease progression by lowering mHTT levels in the brain. Also, CRISPR/Cas9 and other gene editing approaches can potentially edit the mutant HTT gene directly, correcting the genetic mutation responsible for HD or modifying its expression.
Supportive care strategies are integral to managing the complex needs of HD patients and addressing the disease’s broader impact on their lives. HD patients benefit from care provided by multidisciplinary teams, including neurologists, genetic counselors, psychiatrists, physical therapists, occupational therapists, and social workers. This comprehensive approach addresses HD’s diverse medical, psychological, and social aspects.
The UK develops specialized healthcare services and infrastructure to meet the needs of individuals with HD. This includes HD clinics staffed by multidisciplinary teams of neurologists, genetic counselors, psychologists, and social workers. These clinics provide comprehensive care and support tailored to the complex needs of HD patients and their families. As per Brain Research UK, around 7,000 people are living with Huntington’s disease (HD) in the UK. In conclusion, the prevalence of Huntington’s disease in the region is driving the market's growth.
Free Valuable Insights: The Global Huntington's Disease Treatment Market will Hit USD 805.1 Million by 2031, at a CAGR of 9.0%
Based on Drug Type, the market is segmented into Approved Drugs (Tetrabenazine and Deutetrabenazine) and Offlabel Drugs. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Store & Retail Pharmacies, and Online Pharmacies. Based on Age, the market is segmented into Below 50 years and Above 50 years. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
By Drug Type
By Distribution Channel
By Age
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 